<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugResultsOutput hits="20" offset="0" totalResults="10100"><SearchResults><Drug id="99997" name="CA-4948" lastModificationDate="2019-06-25T00:00:00Z" phaseHighest="Phase 1 Clinical"><CompanyOriginator>Aurigene Discovery Technologies Ltd</CompanyOriginator><CompaniesPrimary><Company>Aurigene Discovery Technologies Ltd</Company><Company>Curis Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Acute myelogenous leukemia</Indication><Indication>Diffuse large B-cell lymphoma</Indication><Indication>Lymphoplasmacytic lymphoma</Indication><Indication>Myelodysplastic syndrome</Indication><Indication>Non-Hodgkin lymphoma</Indication></IndicationsPrimary><ActionsPrimary><Action>IRAK-4 protein kinase inhibitor</Action></ActionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Aurigene Discovery Technologies , in collaboration with Curis, is developing CA-4948 (AU-4948), an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor, for the potential oral treatment of hematological cancers, including non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and Waldenstrom's macroglobulinemia (WM). The company is also investigating CA-4948, for the potential treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [ 1711248 ], [ 1711342 ], [ 1738828</Summary><IndicationsSecondary><Indication>Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer protein kinase inhibitor</Action><Action>Synergist</Action></ActionsSecondary><AddedDate>2015-11-24T00:00:00Z</AddedDate></Drug><Drug id="99992" name="F-001" lastModificationDate="2019-03-04T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Array BioPharma Inc</CompanyOriginator><CompaniesPrimary><Company>Array BioPharma Inc</Company><Company>Loxo Oncology Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication></IndicationsPrimary><ActionsPrimary><Action>FGF1 receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Array BioPharma , in collaboration with Loxo Oncology (a wholly-owned subsidiary of Eli Lilly ) is investigating FGFR kinase inhibitors for the potential treatment of cancer [ 1711252 ] [ 1706735 ], [ 2120040 ]. In November 2015, preclinical data were presented [ 1711252 ], [ 1706735 ].</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondary><AddedDate>2015-11-26T00:00:00Z</AddedDate></Drug><Drug id="99986" name="anti PRLR antibody drug-conjugates (cancer), Regeneron Pharmaceuticals" lastModificationDate="2019-05-13T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Regeneron Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Regeneron Pharmaceuticals Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Breast tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>Erbb2 tyrosine kinase receptor modulator</Action><Action>Prolactin receptor modulator</Action></ActionsPrimary><Technologies><Technology>Antibody drug conjugate</Technology><Technology>Biological therapeutic</Technology></Technologies><Summary>Regeneron Pharmaceuticals is investigating anti-prolactin receptor (anti-PRLR) antibody-drug conjugates (ADCs) for the potential treatment of PRLR-positive breast cancer [ 1711112 ]. In November 2015, preclinical data were presented [ 1711112 ]. In January 2018, preclinical studies were ongoing [ 1998683 ].</Summary><ActionsSecondary><Action>Anticancer antibody</Action></ActionsSecondary><AddedDate>2015-11-24T00:00:00Z</AddedDate></Drug><Drug id="99984" name="DZ-2384" lastModificationDate="2016-11-21T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Diazon Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Diazon Pharmaceuticals Inc</Company><Company>McGill University</Company><Company>University of California</Company><Company>University of Texas Southwestern Medical Center</Company></CompaniesPrimary><IndicationsPrimary><Indication>Pancreatic ductal adenocarcinoma</Indication></IndicationsPrimary><Technologies><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Diazon pharmaceuticals , McGill University , University of Texas Southwestern Medical Center and University of California are investigating DZ-2384, a synthetic analog of diazonamide A that targets and depolymerize microtubules, for the potential treatment of pancreatic ductal adenocarcinoma [ 1711246 ], [ 1715351 ]. In November 2015, preclinical data were presented [ 1711246 ].</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondary><AddedDate>2015-11-24T00:00:00Z</AddedDate></Drug><Drug id="99973" name="anti-CD3/anti-EGFR bispecific T cell-engager (Probody/Pb-TCB, cancer), CytomX/Amgen" lastModificationDate="2019-04-11T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>CytomX Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Amgen Inc</Company><Company>CytomX Therapeutics Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication></IndicationsPrimary><ActionsPrimary><Action>CD3 modulator</Action><Action>Epidermal growth factor receptor modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology></Technologies><Summary>CytomX Therapeutics and licensee Amgen are investigating a bispecific Probody T cell-engaging therapeutic (Pb-TCB) targeting CD3 and EGFR for the potential treatment of cancer. In November 2015, preclinical data were presented [ 1711263 ], [ 1967290 ]. In July 2016, the program was listed as being in discovery [ 1779739 ]. In October 2017, it was noted that CytomX was to lead early clinical development, while Amgen would lead later development and commercialization [ 1967290 ].</Summary><ActionsSecondary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99970" name="anti-CD3/anti-PSMA bispecific T-cell engager (prostate cancer), Regeneron" lastModificationDate="2019-04-12T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Regeneron Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Regeneron Pharmaceuticals Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Prostate tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>CD3 modulator</Action><Action>Glutamate carboxypeptidase II modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Humanized antibody</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Multivalent monoclonal antibody</Technology></Technologies><Summary>Regeneron Pharmaceuticals is investigating fully human IgG bispecific antibodies that bind to prostate specific membrane antigen (PSMA) and CD3, for the potential treatment of prostate cancer. In November 2015, preclinical data were presented [ 1711251 ].</Summary><ActionsSecondary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99962" name="SMYD3 histone methyltransferase inhibitors (cancer), Epizyme" lastModificationDate="2016-03-30T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Epizyme Inc</CompanyOriginator><CompaniesPrimary><Company>Epizyme Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication></IndicationsPrimary><ActionsPrimary><Action>SET MYND domain containing protein 3 inhibitor</Action></ActionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Epizyme is investigating a bisubstrate su(var)3-9 and enhancer of zeste (SET) and myeloid, Nervy, and DEAF-1 (MYND) domain containing 3 (SMYD3) inhibitors including EPZ-030456 and EPZ-031686, for the potential treatment of cancer [ 1711161 ]. In March 2016, preclinical data were presented 1741198 ].</Summary><ActionsSecondary><Action>Anticancer</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99960" name="MYX-135" lastModificationDate="2016-11-10T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>DNAtrix Inc</CompanyOriginator><CompaniesPrimary><Company>DNAtrix Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Hematological neoplasm</Indication></IndicationsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Virus novel</Technology></Technologies><Summary>DNAtrix is investigating MYX-135, a myxoma virus based on the University of Florida 's myxoma virus platform, which destroys cancer cells without affecting normal human cells, for the potential treatment of hematological malignancies after myeloablative chemotherapy [ 1714974 ], [ 1871007 ]. In November 2015, the program was listed as being in discovery [ 1714974 ].</Summary><ActionsSecondary><Action>Anticancer</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99957" name="DNX-2450" lastModificationDate="2018-04-23T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>DNAtrix Inc</CompanyOriginator><CompaniesPrimary><Company>DNAtrix Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Solid tumor</Indication></IndicationsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Virus novel</Technology></Technologies><Summary>DNAtrix is investigating DNX-2450, an undisclosed T-cell stimulator armed DNX virus, for the potential treatment of solid tumor. In November 2015, the program was listed as being in discovery [ 1714974 ]. In April 2018, this was still the case [ 2025780 ].</Summary><ActionsSecondary><Action>Anticancer</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2015-11-26T00:00:00Z</AddedDate></Drug><Drug id="99955" name="adalimumab biosimilar, Sinocelltech/Sino Biological" lastModificationDate="2019-04-22T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Sinocelltech Ltd</CompanyOriginator><CompaniesPrimary><Company>Sino Biological Inc</Company><Company>Sinocelltech Ltd</Company></CompaniesPrimary><IndicationsPrimary><Indication>Psoriasis</Indication></IndicationsPrimary><ActionsPrimary><Action>TNF alpha ligand inhibitor</Action><Action>TNF binding agent</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Biosimilar product</Technology><Technology>DNA technology</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><Summary>Sinocelltech , in collaboration with Sino Biological , is investigating a biosimilar version of adalimumab , a recombinant human mAb that inhibits TNF alpha, for the potential injectable treatment of moderate to severe plaque psoriasis [ 1710021 ], [ 1928192 ]. In January 2019, a phase I trial was planned in healthy Chinese male subjects [ 2143756 ]. In June 2019, a phase III trial for moderate to severe plaque psoriasis was planned in China [ 2164185 ], [ 2164193 ].</Summary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99944" name="JTX-4014" lastModificationDate="2019-06-28T00:00:00Z" phaseHighest="Phase 1 Clinical"><CompanyOriginator>Jounce Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Jounce Therapeutics Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Advanced solid tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>Programmed cell death protein 1 inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology></Technologies><Summary>Jounce Therapeutics is developing JTX-4014, a fully human IgG4 monoclonal antibody designed to specifically bind to PD-1 on T effector cells and block its interaction with its ligands, PD-L1 and PD-L2, to augment anti-tumor T cell activity, for the potential treatment of cancer including solid tumors [ 1714610 ], [ 1997026 ], [ 2108124 ]. In December 2018, a phase I study was initiated [ 2108124 ]. In July 2016, Celgene acquired an option to license the agent [ 1781228 ].</Summary><IndicationsSecondary><Indication>Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer monoclonal antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99943" name="exon 43-skipping phosphorodiamidate morpholino oligomer (Duchenne muscular dystrophy), Sarepta Therapeutics" lastModificationDate="2018-07-06T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Sarepta Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Sarepta Therapeutics Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Duchenne dystrophy</Indication></IndicationsPrimary><ActionsPrimary><Action>DMD gene modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oligonucleotide antisense</Technology><Technology>RNA antisense</Technology></Technologies><Summary>Sarepta Therapeutics is investigating a phosphorodiamidate morpholino oligomer (PMO)-based antisense RNA therapeutic, targeted to skip dystrophin gene exon 43, based on its proprietary RNA technology platform, for the potential treatment of Duchenne muscular dystrophy (DMD). In November 2015, the drug was listed as being in discovery [ 1714659 ]. In March 2018, an exon 43-targeted PMO therapy was still in the discovery stage [ 2011155 ].</Summary><ActionsSecondary><Action>Muscle system agent</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99942" name="exon 35-skipping phosphorodiamidate morpholino oligomer (Duchenne muscular dystrophy), Sarepta Therapeutics" lastModificationDate="2018-07-06T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Sarepta Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Sarepta Therapeutics Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Duchenne dystrophy</Indication></IndicationsPrimary><ActionsPrimary><Action>DMD gene modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oligonucleotide antisense</Technology><Technology>RNA antisense</Technology></Technologies><Summary>Sarepta Therapeutics is investigating a phosphorodiamidate morpholino oligomer (PMO)-based antisense RNA therapeutic, targeted to skip dystrophin gene exon 35, based on its proprietary RNA technology platform, for the potential treatment of Duchenne muscular dystrophy (DMD). In November 2015, the drug was listed as being in discovery [ 1714659 ]. In March 2018, an exon 35-targeted PMO therapy was still in the discovery stage [ 2011155 ].</Summary><ActionsSecondary><Action>Muscle system agent</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99941" name="stromal cell modulator therapy (cancer), Jounce" lastModificationDate="2017-02-20T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Jounce Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Jounce Therapeutics Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication></IndicationsPrimary><Technologies><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Jounce Therapeutics is investigating an immunotherapy, which modulates undisclosed targets on stromal cells, for the potential treatment of cancer. In November 2015, the program was in discovery [ 1714610 ]; in February 2017, this was still the case [ 1900926 ].</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Immunomodulator</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99940" name="macrophage and stromal cell modulator therapy (cancer), Jounce" lastModificationDate="2018-01-15T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Jounce Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Jounce Therapeutics Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication></IndicationsPrimary><Technologies><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Jounce Therapeutics is investigating an immunotherapy, which modulates undisclosed targets on macrophage and stromal cells, for the potential treatment of cancer [ 1714610 ]. In January 2018, preclinical studies were ongong with lead program data expected in 2018 [ 1997026 ].</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Macrophage modulator</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99938" name="MT-1" lastModificationDate="2018-03-12T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Jounce Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Jounce Therapeutics Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Cancer</Indication></IndicationsPrimary><Technologies><Technology>Immuno-oncology</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Jounce Therapeutics is investigating MT-1, an immunotherapy which acts by disrupting the interaction of targets on tumor-associated macrophages, for the potential treatment of cancer. In November 2015, the program was listed as being in discovery [ 1714610 ]; in February 2017, this was still the case [ 1900926 ]. In March 2018, the company had advanced the drug into IND-enabling activities [ 2011914 ]. In July 2016, Celgene acquired an option to license early stage programs targeting B cells, T regulatory</Summary><ActionsSecondary><Action>Anticancer</Action><Action>Immunomodulator</Action><Action>Macrophage modulator</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99933" name="radiotherapeutics (acute radiation syndrome), Medisyn/Humanetics" lastModificationDate="2015-11-23T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Medisyn Technologies Inc</CompanyOriginator><CompaniesPrimary><Company>Humanetics Corp</Company><Company>Medisyn Technologies Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Radiation sickness</Indication></IndicationsPrimary><Technologies><Technology>Natural product</Technology></Technologies><Summary>null</Summary><ActionsSecondary><Action>Radiotherapeutic</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99931" name="radioprotectants (acute radiation syndrome), Medisyn/Humanetics" lastModificationDate="2019-05-13T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>Medisyn Technologies Inc</CompanyOriginator><CompaniesPrimary><Company>Humanetics Corp</Company><Company>Medisyn Technologies Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Radiation sickness</Indication></IndicationsPrimary><Technologies><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Medisyn Technologies and Humanetics are investigating radioprotectants for the potential treatment of acute radiation syndrome. In November 2015, the program was listed on the company's pipeline but the status of development was undisclosed [ 1714587 ].</Summary><ActionsSecondary><Action>Radioprotectant</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99930" name="Mab-AR-9.6" lastModificationDate="2019-06-11T00:00:00Z" phaseHighest="Discovery"><CompanyOriginator>University of Nebraska</CompanyOriginator><CompaniesPrimary><Company>AmrutBio</Company><Company>OncoCare Therapeutics Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Pancreas tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>Mucin 16 inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Monoclonal antibody</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><Summary>Quest PharmaTech , through its subsidiary AmrutBio (under license from University of Nebraska ), and US licensee OncoCare Therapeutics are investigating Mab-AR-9.6, a monoclonal antibody against truncated O-glycan on MUC16, for the potential treatment of pancreatic cancer [ 1714483 ], [ 1804770 ], [ 1804772 ], [ 2099721 ]. In January 2016, in vivo data were presented [ 1804772 ]. In November 2018, further development was planned [ 2099721 ].</Summary><CompaniesSecondary><Company>Quest PharmaTech Inc</Company><Company>University of Nebraska</Company></CompaniesSecondary><IndicationsSecondary><Indication>Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer monoclonal antibody</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug><Drug id="99926" name="18F-GTP1" lastModificationDate="2017-10-05T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Genentech Inc</CompanyOriginator><CompaniesPrimary><Company>Genentech Inc</Company></CompaniesPrimary><IndicationsPrimary><Indication>Alzheimers disease</Indication></IndicationsPrimary><ActionsPrimary><Action>Tau protein modulator</Action></ActionsPrimary><Technologies><Technology>Imaging</Technology><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Radiolabeling</Technology></Technologies><Summary>Genentech is developing a radiolabeled, tau-binding probe, 18F-Genentech Tau Probe 1 ([18F]-GTP1, RO-6880276), as a potential PET imaging agent for diagnosis of Alzheimer's disease (AD) [ 1714444 ], [ 1967612 ]. In September 2017, a phase II trial was initiated in patients with AD [ 1967612 ].</Summary><ActionsSecondary><Action>CNS diagnostic agent</Action><Action>PET contrast agent</Action><Action>Radiodiagnostic</Action></ActionsSecondary><AddedDate>2015-11-23T00:00:00Z</AddedDate></Drug></SearchResults><Filters total="15"><Filter label="Drug Sales 2010 (USD M)" name="drugSalesYearActual" total="5"><FilterOption count="566" label="&lt; 100"/><FilterOption count="91" label="≥ 100 and  250"/><FilterOption count="71" label="≥ 250 and  500"/><FilterOption count="57" label="≥ 500 and  1000"/><FilterOption count="72" label="≥ 1000"/></Filter><Filter label="Secondary Actions" name="actionsSecondary" total="100"><FilterOption id="1545" count="2274" label="Anticancer"/><FilterOption id="59620" count="1506" label="Unspecified drug target"/><FilterOption id="2953" count="1300" label="Anti-inflammatory"/><FilterOption id="393" count="885" label="Immunostimulant"/><FilterOption id="991" count="703" label="Antiviral"/><FilterOption id="7761" count="689" label="T-lymphocyte stimulator"/><FilterOption id="55685" count="555" label="Anticancer monoclonal antibody"/><FilterOption id="62255" count="523" label="Anticancer protein kinase inhibitor"/><FilterOption id="2946" count="521" label="Analgesic"/><FilterOption id="1615" count="516" label="Neuroprotectant"/><FilterOption id="1594" count="423" label="Antibacterial"/><FilterOption id="55684" count="419" label="Anticancer antibody"/><FilterOption id="1596" count="383" label="Immunomodulator"/><FilterOption id="12379" count="382" label="Therapeutic vaccine"/><FilterOption id="12378" count="351" label="Prophylactic vaccine"/><FilterOption id="399" count="295" label="Hypoglycemic agent"/><FilterOption id="1589" count="258" label="Apoptosis stimulator"/><FilterOption id="15128" count="208" label="Ophthalmological agent"/><FilterOption id="4790" count="203" label="Genetically engineered autologous cell therapy"/><FilterOption id="2657" count="193" label="Antihypertensive"/><FilterOption id="4781" count="189" label="Adeno-associated virus based gene therapy"/><FilterOption id="2947" count="171" label="Antiparkinsonian"/><FilterOption id="61" count="169" label="Angiogenesis inhibitor"/><FilterOption id="7293" count="164" label="Synergist"/><FilterOption id="284" count="151" label="Nootropic agent"/><FilterOption id="12372" count="142" label="Protein subunit vaccine"/><FilterOption id="70" count="119" label="Anticonvulsant agent"/><FilterOption id="12370" count="116" label="Recombinant viral vector vaccine"/><FilterOption id="2941" count="115" label="Antidepressant"/><FilterOption id="767" count="110" label="Cell cycle inhibitor"/><FilterOption id="7220" count="107" label="Neoplasm diagnostic agent"/><FilterOption id="26035" count="107" label="siRNA agent"/><FilterOption id="4155" count="102" label="Imaging agent"/><FilterOption id="1879" count="99" label="DNA vaccine"/><FilterOption id="7294" count="98" label="Antisense oligonucleotide inhibitor"/><FilterOption id="2955" count="98" label="Non-steroidal anti-inflammatory"/><FilterOption id="2943" count="91" label="Antipsychotic"/><FilterOption id="396" count="90" label="Immunosuppressant"/><FilterOption id="2659" count="84" label="Cardioprotectant"/><FilterOption id="1748" count="84" label="Fungicide"/><FilterOption id="7292" count="81" label="Vulnerary agent"/><FilterOption id="7757" count="79" label="Natural killer cell stimulator"/><FilterOption id="12380" count="77" label="Unspecified vaccine"/><FilterOption id="524" count="70" label="Adjuvant"/><FilterOption id="2939" count="70" label="CNS modulator"/><FilterOption id="664" count="68" label="Fibrosuppressant"/><FilterOption id="610" count="66" label="Hematopoietic stimulator"/><FilterOption id="5720" count="66" label="Radiodiagnostic"/><FilterOption id="2942" count="65" label="Anxiolytic"/><FilterOption id="1880" count="65" label="Dermatological agent"/><FilterOption id="1332" count="65" label="Gastrointestinal system agent"/><FilterOption id="2575" count="65" label="Microtubule inhibitor"/><FilterOption id="1470" count="65" label="Respiratory system agent"/><FilterOption id="2954" count="65" label="Steroidal anti-inflammatory"/><FilterOption id="173474" count="64" label="Microbiome modulator"/><FilterOption id="388" count="62" label="Vasodilator"/><FilterOption id="5555" count="61" label="PET contrast agent"/><FilterOption id="50" count="58" label="Anticancer alkylating agent"/><FilterOption id="539" count="56" label="Immunotoxin"/><FilterOption id="71" count="48" label="Antihypercholesterolemic agent"/><FilterOption id="659" count="48" label="Coagulation inhibitor"/><FilterOption id="1408" count="48" label="Muscle system agent"/><FilterOption id="646" count="47" label="Bronchodilator"/><FilterOption id="74" count="46" label="Antioxidant agent"/><FilterOption id="2638" count="46" label="Antiparasitic"/><FilterOption id="2970" count="45" label="Anti-emetic"/><FilterOption id="140" count="44" label="DNA synthesis inhibitor"/><FilterOption id="1532" count="44" label="Viral replication inhibitor"/><FilterOption id="965" count="43" label="Cardiovascular agent"/><FilterOption id="104" count="42" label="Bacterial cell wall synthesis inhibitor"/><FilterOption id="285" count="42" label="Norepinephrine uptake inhibitor"/><FilterOption id="1467" count="42" label="Renal system agent"/><FilterOption id="12364" count="41" label="Live attenuated viral vaccine"/><FilterOption id="15148" count="41" label="Ocular antineovascularisation agent"/><FilterOption id="15184" count="41" label="Systemic antipsoriatic product"/><FilterOption id="2576" count="40" label="Microtubule stabilizer"/><FilterOption id="72" count="39" label="Antihyperlipidemic agent"/><FilterOption id="7751" count="39" label="Macrophage stimulator"/><FilterOption id="695" count="39" label="Metastasis inhibitor"/><FilterOption id="7211" count="38" label="CNS diagnostic agent"/><FilterOption id="3189" count="38" label="Corticosteroid agonist"/><FilterOption id="1538" count="37" label="Bacterial protein synthesis inhibitor"/><FilterOption id="102926" count="37" label="Dendritic cell vaccine"/><FilterOption id="312" count="37" label="Platelet aggregation inhibitor"/><FilterOption id="53558" count="37" label="Stem cell modulator"/><FilterOption id="7018" count="36" label="Antihypertriglyceridemic agent"/><FilterOption id="968" count="35" label="Coagulation stimulator"/><FilterOption id="173472" count="35" label="Dendritic cell stimulator"/><FilterOption id="15187" count="35" label="Systemic dermatological antibacterial product"/><FilterOption id="3" count="34" label="5-HT uptake inhibitor"/><FilterOption id="89" count="34" label="Bone resorption inhibitor"/><FilterOption id="5692" count="34" label="T-lymphocyte modulator"/><FilterOption id="1593" count="33" label="Antimicrobial"/><FilterOption id="4780" count="32" label="Adenovirus based gene therapy"/><FilterOption id="1569" count="31" label="Anticancer antimetabolite"/><FilterOption id="1465" count="31" label="Radioprotectant"/><FilterOption id="62" count="30" label="Angiogenesis stimulator"/><FilterOption id="1546" count="30" label="Blood system agent"/><FilterOption id="747" count="30" label="HIV replication inhibitor"/><FilterOption id="38419" count="30" label="miRNA agent"/></Filter><Filter label="Drug Deal Types" name="drugDealTypes" total="20"><FilterOption id="4" count="2623" label="Drug - Development/Commercialization License"/><FilterOption id="13" count="1711" label="Drug - Funding"/><FilterOption id="3" count="1324" label="Drug - Early Research/Development"/><FilterOption id="5" count="838" label="Drug - Commercialization License"/><FilterOption id="7" count="774" label="Drug - Development Services"/><FilterOption id="6" count="716" label="Drug - Manufacturing/Supply"/><FilterOption id="10" count="488" label="Technology - Other Proprietary"/><FilterOption id="11" count="387" label="Patent - Exclusive Rights"/><FilterOption id="2" count="287" label="Drug - Screening/Evaluation"/><FilterOption id="14" count="281" label="Drug - Asset Divestment"/><FilterOption id="8" count="249" label="Technology - Delivery/Formulation"/><FilterOption id="1" count="169" label="Drug - Discovery/Design"/><FilterOption id="20" count="136" label="Company - M&amp;A (in whole or part)"/><FilterOption id="15" count="98" label="Drug - CRADA"/><FilterOption id="12" count="67" label="Patent - Non-Exclusive Rights"/><FilterOption id="19" count="40" label="Company - Joint Venture"/><FilterOption id="21" count="23" label="Patent - Litigation Settlement"/><FilterOption id="17" count="16" label="Patent - Asset Divestment"/><FilterOption id="16" count="10" label="Technology - Asset Divestment"/><FilterOption id="9" count="6" label="Technology - Target Validation"/></Filter><Filter label="Drug Forecast 2015 (USD M)" name="drugSalesYearEstimate" total="5"><FilterOption count="369" label="&lt; 100"/><FilterOption count="123" label="≥ 100 and  250"/><FilterOption count="80" label="≥ 250 and  500"/><FilterOption count="57" label="≥ 500 and  1000"/><FilterOption count="77" label="≥ 1000"/></Filter><Filter label="Drug Deals Count" name="drugDealsCount" total="8"><FilterOption count="4358" label="= 0"/><FilterOption count="2853" label="&gt; 1 and ≤ 1"/><FilterOption count="1163" label="&gt; 2 and ≤ 2"/><FilterOption count="591" label="&gt; 3 and ≤ 3"/><FilterOption count="370" label="&gt; 4 and ≤ 4"/><FilterOption count="226" label="&gt; 5 and ≤ 5"/><FilterOption count="403" label="&gt; 6 and ≤ 10"/><FilterOption count="136" label="&gt; 11"/></Filter><Filter label="Technologies" name="technologies" total="100"><FilterOption id="762" count="5205" label="Small molecule therapeutic"/><FilterOption id="761" count="4611" label="Biological therapeutic"/><FilterOption id="585" count="2172" label="Oral formulation"/><FilterOption id="766" count="1906" label="Parenteral formulation unspecified"/><FilterOption id="648" count="1528" label="Intravenous formulation"/><FilterOption id="740" count="999" label="Infusion"/><FilterOption id="1263" count="773" label="Immuno-oncology"/><FilterOption id="85" count="704" label="Protein recombinant"/><FilterOption id="595" count="691" label="Tablet formulation"/><FilterOption id="80" count="604" label="Peptide"/><FilterOption id="84" count="496" label="Protein fusion"/><FilterOption id="647" count="482" label="Subcutaneous formulation"/><FilterOption id="586" count="455" label="Capsule formulation"/><FilterOption id="175" count="454" label="Drug combination"/><FilterOption id="62" count="394" label="Virus recombinant"/><FilterOption id="589" count="356" label="Sustained release formulation"/><FilterOption id="169" count="327" label="Monoclonal antibody humanized"/><FilterOption id="168" count="300" label="Monoclonal antibody human"/><FilterOption id="573" count="284" label="Immunoglobulin-G"/><FilterOption id="135" count="272" label="T-lymphocyte"/><FilterOption id="611" count="253" label="Dermatological formulation"/><FilterOption id="66" count="246" label="Antibiotic"/><FilterOption id="620" count="246" label="Ophthalmic formulation"/><FilterOption id="1668" count="245" label="Nanoparticle formulation"/><FilterOption id="651" count="240" label="Intramuscular formulation"/><FilterOption id="603" count="239" label="Systemic formulation unspecified"/><FilterOption id="103" count="237" label="Oligonucleotide"/><FilterOption id="746" count="231" label="Solution"/><FilterOption id="1" count="227" label="Antibody"/><FilterOption id="1647" count="217" label="Natural product"/><FilterOption id="1652" count="217" label="Prodrug"/><FilterOption id="345" count="211" label="Receptor chimeric"/><FilterOption id="51" count="205" label="Monoclonal antibody"/><FilterOption id="1247" count="194" label="Chimeric antigen receptor T cell therapy"/><FilterOption id="558" count="183" label="Transdermal formulation"/><FilterOption id="962" count="182" label="Biosimilar product"/><FilterOption id="731" count="158" label="Imaging"/><FilterOption id="616" count="157" label="Inhalant formulation"/><FilterOption id="596" count="156" label="Injectable formulation"/><FilterOption id="569" count="153" label="Oligonucleotide antisense"/><FilterOption id="751" count="148" label="Film coating"/><FilterOption id="570" count="138" label="Cell therapy"/><FilterOption id="267" count="133" label="Multivalent antibody"/><FilterOption id="660" count="127" label="Oral sustained release formulation"/><FilterOption id="1164" count="122" label="Antibody drug conjugate"/><FilterOption id="171" count="117" label="Monoclonal antibody conjugated"/><FilterOption id="207" count="116" label="Protein conjugated"/><FilterOption id="180" count="115" label="Antibody fragment"/><FilterOption id="599" count="114" label="Nanoparticle formulation injectable"/><FilterOption id="724" count="110" label="Radiolabeling"/><FilterOption id="898" count="99" label="Formulation powder"/><FilterOption id="750" count="97" label="Freeze drying"/><FilterOption id="745" count="92" label="Suspension"/><FilterOption id="216" count="91" label="Antibody conjugated"/><FilterOption id="348" count="91" label="PEGylated formulation"/><FilterOption id="170" count="89" label="Multivalent monoclonal antibody"/><FilterOption id="67" count="83" label="Antigen"/><FilterOption id="901" count="82" label="Recombinant enzyme"/><FilterOption id="90" count="82" label="Steroid"/><FilterOption id="538" count="81" label="Humanized antibody"/><FilterOption id="600" count="81" label="Patch formulation"/><FilterOption id="680" count="75" label="Buccal formulation systemic"/><FilterOption id="659" count="73" label="Ophthalmic liquid formulation"/><FilterOption id="347" count="72" label="Intratumoral formulation"/><FilterOption id="349" count="71" label="Lipid"/><FilterOption id="617" count="67" label="Aerosol formulation inhalant"/><FilterOption id="612" count="66" label="Emulsion dermatological"/><FilterOption id="142" count="66" label="Liposome formulation"/><FilterOption id="166" count="64" label="Chimeric monoclonal antibody"/><FilterOption id="594" count="64" label="Oral suspension formulation"/><FilterOption id="641" count="62" label="Controlled release formulation"/><FilterOption id="593" count="62" label="Oral liquid formulation"/><FilterOption id="559" count="61" label="Oral controlled release formulation"/><FilterOption id="74" count="59" label="Glycoprotein"/><FilterOption id="764" count="59" label="Local formulation unspecified"/><FilterOption id="851" count="58" label="Intradermal formulation"/><FilterOption id="805" count="52" label="Daily dosing"/><FilterOption id="856" count="51" label="Autologous stem cell therapy"/><FilterOption id="753" count="51" label="Microparticle formulation"/><FilterOption id="667" count="51" label="Peptidomimetic"/><FilterOption id="1246" count="50" label="T-lymphocyte cell therapy"/><FilterOption id="94" count="49" label="RNA antisense"/><FilterOption id="661" count="48" label="Oral quick release formulation"/><FilterOption id="93" count="48" label="Toxin"/><FilterOption id="775" count="47" label="Dermatological gel formulation"/><FilterOption id="777" count="47" label="Nasal formulation"/><FilterOption id="894" count="46" label="Liquid formulation"/><FilterOption id="1656" count="44" label="CNS formulation"/><FilterOption id="884" count="44" label="Haematopoietic stem cell therapy"/><FilterOption id="159" count="44" label="Oligosaccharide"/><FilterOption id="56" count="43" label="Bacteria recombinant"/><FilterOption id="857" count="42" label="Allogenic stem cell therapy"/><FilterOption id="215" count="41" label="Antigen presentation system"/><FilterOption id="902" count="41" label="Orally disintegrating tablet"/><FilterOption id="1646" count="40" label="Injectable controlled release formulation"/><FilterOption id="623" count="40" label="Vaginal formulation"/><FilterOption id="4" count="39" label="Immunoglobulin"/><FilterOption id="654" count="38" label="Intrathecal formulation"/><FilterOption id="582" count="37" label="Antibody polyclonal"/><FilterOption id="1245" count="37" label="Lymphocyte cell therapy"/></Filter><Filter label="Drug Added by Day" name="drugAddedDateByDay" total="100"><FilterOption count="398" label="1996-02-16"/><FilterOption count="145" label="2019-01-08"/><FilterOption count="79" label="2016-08-31"/><FilterOption count="76" label="2016-10-27"/><FilterOption count="65" label="2015-08-01"/><FilterOption count="65" label="2016-12-20"/><FilterOption count="54" label="2015-05-13"/><FilterOption count="54" label="2017-11-06"/><FilterOption count="49" label="2014-04-09"/><FilterOption count="46" label="2015-05-14"/><FilterOption count="46" label="2019-05-13"/><FilterOption count="45" label="2018-09-11"/><FilterOption count="43" label="2016-07-15"/><FilterOption count="42" label="2018-03-20"/><FilterOption count="39" label="2017-12-26"/><FilterOption count="37" label="2015-10-22"/><FilterOption count="37" label="2017-04-18"/><FilterOption count="35" label="2018-05-02"/><FilterOption count="34" label="2017-09-18"/><FilterOption count="34" label="2018-05-11"/><FilterOption count="31" label="2016-06-04"/><FilterOption count="31" label="2017-01-02"/><FilterOption count="30" label="2017-03-01"/><FilterOption count="28" label="2014-09-18"/><FilterOption count="27" label="2017-01-11"/><FilterOption count="27" label="2017-01-12"/><FilterOption count="26" label="2015-11-23"/><FilterOption count="26" label="2017-09-26"/><FilterOption count="25" label="2016-10-24"/><FilterOption count="24" label="2016-05-26"/><FilterOption count="24" label="2016-09-29"/><FilterOption count="24" label="2017-01-30"/><FilterOption count="23" label="2015-04-29"/><FilterOption count="23" label="2017-03-06"/><FilterOption count="23" label="2017-04-21"/><FilterOption count="23" label="2019-06-16"/><FilterOption count="22" label="2016-03-10"/><FilterOption count="22" label="2016-05-07"/><FilterOption count="22" label="2017-04-06"/><FilterOption count="22" label="2017-06-09"/><FilterOption count="22" label="2017-12-21"/><FilterOption count="22" label="2018-03-14"/><FilterOption count="21" label="2015-06-22"/><FilterOption count="21" label="2016-12-26"/><FilterOption count="20" label="2015-12-15"/><FilterOption count="20" label="2016-04-25"/><FilterOption count="20" label="2016-06-27"/><FilterOption count="20" label="2016-09-27"/><FilterOption count="20" label="2016-11-21"/><FilterOption count="20" label="2017-08-21"/><FilterOption count="19" label="2016-06-15"/><FilterOption count="19" label="2016-07-25"/><FilterOption count="19" label="2019-04-04"/><FilterOption count="19" label="2019-05-30"/><FilterOption count="18" label="2016-05-23"/><FilterOption count="18" label="2016-07-18"/><FilterOption count="18" label="2016-12-07"/><FilterOption count="18" label="2019-02-21"/><FilterOption count="18" label="2019-05-02"/><FilterOption count="17" label="2014-12-06"/><FilterOption count="17" label="2017-09-13"/><FilterOption count="17" label="2019-03-01"/><FilterOption count="17" label="2019-03-16"/><FilterOption count="16" label="2015-09-11"/><FilterOption count="16" label="2016-05-10"/><FilterOption count="16" label="2017-03-16"/><FilterOption count="16" label="2017-10-27"/><FilterOption count="16" label="2018-03-07"/><FilterOption count="16" label="2018-05-03"/><FilterOption count="16" label="2018-08-14"/><FilterOption count="16" label="2019-04-29"/><FilterOption count="15" label="2012-08-28"/><FilterOption count="15" label="2013-10-30"/><FilterOption count="15" label="2015-01-09"/><FilterOption count="15" label="2015-06-18"/><FilterOption count="15" label="2016-04-21"/><FilterOption count="15" label="2017-04-27"/><FilterOption count="15" label="2019-01-11"/><FilterOption count="14" label="2011-07-05"/><FilterOption count="14" label="2013-12-04"/><FilterOption count="14" label="2015-09-09"/><FilterOption count="14" label="2016-03-03"/><FilterOption count="14" label="2016-08-13"/><FilterOption count="14" label="2017-10-24"/><FilterOption count="14" label="2018-02-05"/><FilterOption count="13" label="2015-09-29"/><FilterOption count="13" label="2015-11-17"/><FilterOption count="13" label="2016-03-01"/><FilterOption count="13" label="2017-10-05"/><FilterOption count="13" label="2017-11-13"/><FilterOption count="12" label="2012-07-16"/><FilterOption count="12" label="2015-11-06"/><FilterOption count="12" label="2016-03-22"/><FilterOption count="12" label="2016-07-05"/><FilterOption count="12" label="2017-03-28"/><FilterOption count="12" label="2018-02-22"/><FilterOption count="12" label="2019-06-20"/><FilterOption count="11" label="2014-12-12"/><FilterOption count="11" label="2015-09-21"/><FilterOption count="11" label="2016-01-12"/></Filter><Filter label="Drug Has Financials" name="drugHasFinancials" total="2"><FilterOption count="9254" label="No"/><FilterOption count="846" label="Yes"/></Filter><Filter label="Secondary Companies" name="companiesSecondary" total="100"><FilterOption id="13601" count="53" label="Abbott Laboratories"/><FilterOption id="18767" count="53" label="Pfizer Inc"/><FilterOption id="19711" count="51" label="Schering-Plough Corp"/><FilterOption id="28355" count="37" label="GlaxoSmithKline plc"/><FilterOption id="14190" count="32" label="AstraZeneca plc"/><FilterOption id="20300" count="30" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="15065" count="29" label="Bristol-Myers Squibb Co"/><FilterOption id="23137" count="29" label="Novartis AG"/><FilterOption id="14112" count="28" label="Wyeth"/><FilterOption id="17810" count="27" label="Eli Lilly &amp; Co"/><FilterOption id="18077" count="27" label="Merck &amp; Co Inc"/><FilterOption id="27638" count="26" label="Pharmacia Corp"/><FilterOption id="1013295" count="22" label="Astellas Pharma Inc"/><FilterOption id="22122" count="22" label="Memorial Sloan-Kettering Cancer Center"/><FilterOption id="1009547" count="22" label="Sanofi SA"/><FilterOption id="14455" count="21" label="Bayer AG"/><FilterOption id="17808" count="21" label="Ligand Pharmaceuticals Inc"/><FilterOption id="15873" count="20" label="Elan Corp plc"/><FilterOption id="19446" count="19" label="Roche Holding AG"/><FilterOption id="20518" count="18" label="National Institutes of Health"/><FilterOption id="23382" count="17" label="MD Anderson Cancer Center"/><FilterOption id="24652" count="17" label="Shire plc"/><FilterOption id="25623" count="17" label="University of California Los Angeles"/><FilterOption id="22006" count="16" label="Pharmacia &amp; Upjohn Inc"/><FilterOption id="14109" count="15" label="Amgen Inc"/><FilterOption id="1083827" count="15" label="bioCSL PTY Ltd"/><FilterOption id="20679" count="15" label="Stanford University"/><FilterOption id="17058" count="14" label="Bausch Health Companies Inc"/><FilterOption id="19687" count="14" label="Bayer Schering Pharma AG"/><FilterOption id="1005244" count="14" label="Biogen Inc"/><FilterOption id="17332" count="14" label="Johnson &amp; Johnson"/><FilterOption id="20519" count="14" label="National Cancer Institute"/><FilterOption id="1039991" count="14" label="Nationwide Children's Hospital"/><FilterOption id="25451" count="14" label="University of California San Diego"/><FilterOption id="22413" count="13" label="Biovail Corp"/><FilterOption id="1018015" count="13" label="Signature Therapeutics Inc"/><FilterOption id="25218" count="12" label="Aventis Pharma AG"/><FilterOption id="16227" count="12" label="Fujisawa Pharmaceutical Co Ltd"/><FilterOption id="19658" count="12" label="Sankyo Co Ltd"/><FilterOption id="14199" count="12" label="Wyeth Pharmaceuticals"/><FilterOption id="20967" count="12" label="Yamanouchi Pharmaceutical Co Ltd"/><FilterOption id="14042" count="11" label="Allergan Inc"/><FilterOption id="15331" count="11" label="Celgene Corp"/><FilterOption id="16198" count="11" label="Forest Laboratories Inc"/><FilterOption id="19453" count="11" label="Genentech Inc"/><FilterOption id="16453" count="11" label="Glaxo Group Ltd"/><FilterOption id="17327" count="11" label="Japan Tobacco Inc"/><FilterOption id="18954" count="11" label="Meda AB"/><FilterOption id="20315" count="11" label="Tanabe Seiyaku Co Ltd"/><FilterOption id="20575" count="11" label="University of Florida"/><FilterOption id="14437" count="10" label="Baxter International Inc"/><FilterOption id="15563" count="10" label="CSL Ltd"/><FilterOption id="1017506" count="10" label="Daiichi Sankyo Co Ltd"/><FilterOption id="15872" count="10" label="Eisai Co Ltd"/><FilterOption id="28893" count="10" label="King Pharmaceuticals Inc"/><FilterOption id="21159" count="10" label="Sigma-Tau Ind Farm Riunite SpA"/><FilterOption id="20348" count="10" label="Teva Pharmaceutical Industries Ltd"/><FilterOption id="20787" count="10" label="Warner-Lambert Co"/><FilterOption id="20573" count="9" label="Emory University"/><FilterOption id="25224" count="9" label="Hoechst Marion Roussel Inc"/><FilterOption id="17269" count="9" label="Ionis Pharmaceuticals Inc"/><FilterOption id="17661" count="9" label="Kirin Brewery Co Ltd"/><FilterOption id="13880" count="9" label="MSD OSS BV"/><FilterOption id="1011746" count="9" label="PolyMedix Inc"/><FilterOption id="26494" count="9" label="Sanofi-Synthelabo"/><FilterOption id="20547" count="9" label="University of California"/><FilterOption id="30578" count="9" label="VGX Pharmaceuticals LLC"/><FilterOption id="21717" count="8" label="Actavis Inc"/><FilterOption id="1088700" count="8" label="Allergan plc"/><FilterOption id="16881" count="8" label="Astra AB"/><FilterOption id="23133" count="8" label="Aviragen Therapeutics Inc"/><FilterOption id="14129" count="8" label="Cangene Corp"/><FilterOption id="15414" count="8" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="1007047" count="8" label="Epitomics Inc"/><FilterOption id="16450" count="8" label="Gilead Sciences Inc"/><FilterOption id="17900" count="8" label="H Lundbeck A/S"/><FilterOption id="29382" count="8" label="IMPAX Laboratories Inc"/><FilterOption id="17259" count="8" label="Ipsen"/><FilterOption id="19862" count="8" label="Merck Serono SA"/><FilterOption id="1063564" count="8" label="Stemcentrx Inc"/><FilterOption id="25439" count="8" label="United Therapeutics Corp"/><FilterOption id="20634" count="8" label="University of North Carolina"/><FilterOption id="20658" count="8" label="University of Pennsylvania"/><FilterOption id="16955" count="8" label="Zeneca Group plc"/><FilterOption id="14729" count="7" label="Biogen Inc (FL)"/><FilterOption id="20559" count="7" label="Columbia University"/><FilterOption id="15593" count="7" label="Daiichi Seiyaku Co Ltd"/><FilterOption id="18005" count="7" label="Medicis Pharmaceutical Corp"/><FilterOption id="18008" count="7" label="MedImmune LLC"/><FilterOption id="20805" count="7" label="Parke-Davis &amp; Co"/><FilterOption id="23408" count="7" label="Sanofi Pasteur MSD"/><FilterOption id="20623" count="7" label="University of Michigan"/><FilterOption id="15262" count="7" label="Vernalis plc"/><FilterOption id="28429" count="6" label="Academia Sinica"/><FilterOption id="1037667" count="6" label="Albireo Ltd"/><FilterOption id="1032144" count="6" label="AnaptysBio Inc"/><FilterOption id="25902" count="6" label="Array BioPharma Inc"/><FilterOption id="27254" count="6" label="Aventis SA"/><FilterOption id="1171931" count="6" label="Celenex"/><FilterOption id="26178" count="6" label="F Hoffmann-La Roche AG"/></Filter><Filter label="Primary Indications" name="indicationsPrimary" total="100"><FilterOption id="651" count="1551" label="Cancer"/><FilterOption id="725" count="347" label="Solid tumor"/><FilterOption id="20" count="309" label="Pain"/><FilterOption id="49" count="291" label="Breast tumor"/><FilterOption id="14" count="235" label="Alzheimers disease"/><FilterOption id="3713" count="204" label="Advanced solid tumor"/><FilterOption id="188" count="185" label="Inflammatory disease"/><FilterOption id="799" count="169" label="Ovary tumor"/><FilterOption id="1731" count="167" label="Acute myelogenous leukemia"/><FilterOption id="1262" count="165" label="Non-small-cell lung cancer"/><FilterOption id="255" count="158" label="Parkinsons disease"/><FilterOption id="1005" count="156" label="Unidentified indication"/><FilterOption id="36" count="150" label="Autoimmune disease"/><FilterOption id="158" count="147" label="HIV infection"/><FilterOption id="2454" count="145" label="Glioblastoma"/><FilterOption id="291" count="144" label="Rheumatoid arthritis"/><FilterOption id="837" count="137" label="Non-insulin dependent diabetes"/><FilterOption id="40" count="133" label="Bacterial infection"/><FilterOption id="1828" count="132" label="Multiple myeloma"/><FilterOption id="249" count="132" label="Pancreas tumor"/><FilterOption id="276" count="125" label="Prostate tumor"/><FilterOption id="191" count="124" label="Influenza virus infection"/><FilterOption id="3657" count="123" label="Metastatic breast cancer"/><FilterOption id="205" count="115" label="Melanoma"/><FilterOption id="281" count="114" label="Psoriasis"/><FilterOption id="989" count="113" label="Colorectal tumor"/><FilterOption id="319" count="112" label="Non-Hodgkin lymphoma"/><FilterOption id="2054" count="108" label="Hematological neoplasm"/><FilterOption id="2637" count="106" label="Non-alcoholic steatohepatitis"/><FilterOption id="213" count="100" label="Multiple sclerosis"/><FilterOption id="3665" count="98" label="Metastatic non small cell lung cancer"/><FilterOption id="152" count="95" label="Hepatitis B virus infection"/><FilterOption id="1767" count="93" label="Hepatocellular carcinoma"/><FilterOption id="31" count="92" label="Asthma"/><FilterOption id="178" count="89" label="Hypertension"/><FilterOption id="88" count="88" label="Cystic fibrosis"/><FilterOption id="153" count="81" label="Hepatitis C virus infection"/><FilterOption id="238" count="80" label="Obesity"/><FilterOption id="1749" count="77" label="Diffuse large B-cell lymphoma"/><FilterOption id="623" count="77" label="Head and neck tumor"/><FilterOption id="233" count="77" label="Neurodegenerative disease"/><FilterOption id="677" count="77" label="Neurological disease"/><FilterOption id="212" count="76" label="Motor neurone disease"/><FilterOption id="189" count="74" label="Inflammatory bowel disease"/><FilterOption id="1272" count="74" label="Myelodysplastic syndrome"/><FilterOption id="1295" count="74" label="Neuropathic pain"/><FilterOption id="97" count="72" label="Diabetes mellitus"/><FilterOption id="57" count="71" label="Cardiovascular disease"/><FilterOption id="127" count="71" label="Stomach tumor"/><FilterOption id="755" count="70" label="Lung tumor"/><FilterOption id="316" count="68" label="B-cell lymphoma"/><FilterOption id="1185" count="68" label="Chronic obstructive pulmonary disease"/><FilterOption id="119" count="68" label="Epilepsy"/><FilterOption id="3246" count="68" label="Hormone refractory prostate cancer"/><FilterOption id="1734" count="66" label="Chronic lymphocytic leukemia"/><FilterOption id="1108" count="66" label="Glioma"/><FilterOption id="3658" count="66" label="Metastatic colorectal cancer"/><FilterOption id="337" count="66" label="Ulcerative colitis"/><FilterOption id="1102" count="65" label="Atopic dermatitis"/><FilterOption id="3257" count="64" label="Stage IV melanoma"/><FilterOption id="245" count="63" label="Osteoarthritis"/><FilterOption id="84" count="61" label="Crohns disease"/><FilterOption id="746" count="61" label="Infectious disease"/><FilterOption id="203" count="60" label="Lymphoma"/><FilterOption id="2380" count="59" label="Bladder cancer"/><FilterOption id="307" count="59" label="Squamous cell carcinoma"/><FilterOption id="1766" count="58" label="Renal cell carcinoma"/><FilterOption id="836" count="57" label="Insulin dependent diabetes"/><FilterOption id="1049" count="55" label="Ebola virus infection"/><FilterOption id="347" count="55" label="Wound healing"/><FilterOption id="308" count="54" label="Staphylococcus aureus infection"/><FilterOption id="1728" count="53" label="Acute lymphoblastic leukemia"/><FilterOption id="2020" count="53" label="Duchenne dystrophy"/><FilterOption id="134" count="53" label="Glaucoma"/><FilterOption id="299" count="53" label="Schizophrenia"/><FilterOption id="655" count="52" label="Metabolic disorder"/><FilterOption id="1226" count="51" label="Age related macular degeneration"/><FilterOption id="93" count="51" label="Depression"/><FilterOption id="55" count="50" label="Cardiac failure"/><FilterOption id="3669" count="50" label="Metastatic pancreas cancer"/><FilterOption id="344" count="50" label="Viral infection"/><FilterOption id="3354" count="50" label="Wet age related macular degeneration"/><FilterOption id="60" count="49" label="Central nervous system disease"/><FilterOption id="159" count="49" label="HIV-1 infection"/><FilterOption id="239" count="49" label="Ocular disease"/><FilterOption id="1705" count="48" label="Endometrioid carcinoma"/><FilterOption id="210" count="48" label="Migraine"/><FilterOption id="1261" count="48" label="Small-cell lung cancer"/><FilterOption id="1745" count="47" label="Follicle center lymphoma"/><FilterOption id="124" count="47" label="Fungal infection"/><FilterOption id="427" count="47" label="Uterine cervix tumor"/><FilterOption id="4250" count="46" label="Metastatic renal cell carcinoma"/><FilterOption id="287" count="45" label="Respiratory syncytial virus infection"/><FilterOption id="65" count="44" label="Stroke"/><FilterOption id="137" count="43" label="Gram negative bacterium infection"/><FilterOption id="396" count="42" label="Papillomavirus infection"/><FilterOption id="246" count="41" label="Osteoporosis"/><FilterOption id="1815" count="40" label="Bacterial pneumonia"/><FilterOption id="3083" count="40" label="Peritoneal tumor"/><FilterOption id="114" count="40" label="Sepsis"/></Filter><Filter label="Secondary Indications" name="indicationsSecondary" total="100"><FilterOption id="651" count="398" label="Cancer"/><FilterOption id="725" count="120" label="Solid tumor"/><FilterOption id="188" count="77" label="Inflammatory disease"/><FilterOption id="49" count="71" label="Breast tumor"/><FilterOption id="291" count="54" label="Rheumatoid arthritis"/><FilterOption id="36" count="51" label="Autoimmune disease"/><FilterOption id="14" count="50" label="Alzheimers disease"/><FilterOption id="249" count="46" label="Pancreas tumor"/><FilterOption id="1262" count="45" label="Non-small-cell lung cancer"/><FilterOption id="989" count="44" label="Colorectal tumor"/><FilterOption id="799" count="44" label="Ovary tumor"/><FilterOption id="205" count="41" label="Melanoma"/><FilterOption id="1828" count="41" label="Multiple myeloma"/><FilterOption id="276" count="40" label="Prostate tumor"/><FilterOption id="31" count="39" label="Asthma"/><FilterOption id="2054" count="38" label="Hematological neoplasm"/><FilterOption id="20" count="38" label="Pain"/><FilterOption id="93" count="34" label="Depression"/><FilterOption id="837" count="33" label="Non-insulin dependent diabetes"/><FilterOption id="281" count="32" label="Psoriasis"/><FilterOption id="1731" count="31" label="Acute myelogenous leukemia"/><FilterOption id="158" count="30" label="HIV infection"/><FilterOption id="1272" count="30" label="Myelodysplastic syndrome"/><FilterOption id="213" count="28" label="Multiple sclerosis"/><FilterOption id="238" count="28" label="Obesity"/><FilterOption id="1734" count="25" label="Chronic lymphocytic leukemia"/><FilterOption id="60" count="24" label="Central nervous system disease"/><FilterOption id="1185" count="24" label="Chronic obstructive pulmonary disease"/><FilterOption id="677" count="24" label="Neurological disease"/><FilterOption id="1261" count="24" label="Small-cell lung cancer"/><FilterOption id="623" count="23" label="Head and neck tumor"/><FilterOption id="1295" count="23" label="Neuropathic pain"/><FilterOption id="65" count="23" label="Stroke"/><FilterOption id="57" count="22" label="Cardiovascular disease"/><FilterOption id="755" count="22" label="Lung tumor"/><FilterOption id="344" count="22" label="Viral infection"/><FilterOption id="97" count="21" label="Diabetes mellitus"/><FilterOption id="1108" count="21" label="Glioma"/><FilterOption id="189" count="21" label="Inflammatory bowel disease"/><FilterOption id="319" count="21" label="Non-Hodgkin lymphoma"/><FilterOption id="316" count="20" label="B-cell lymphoma"/><FilterOption id="40" count="20" label="Bacterial infection"/><FilterOption id="84" count="20" label="Crohns disease"/><FilterOption id="3246" count="20" label="Hormone refractory prostate cancer"/><FilterOption id="655" count="20" label="Metabolic disorder"/><FilterOption id="337" count="19" label="Ulcerative colitis"/><FilterOption id="100" count="18" label="Diabetic nephropathy"/><FilterOption id="255" count="18" label="Parkinsons disease"/><FilterOption id="299" count="18" label="Schizophrenia"/><FilterOption id="127" count="18" label="Stomach tumor"/><FilterOption id="3713" count="17" label="Advanced solid tumor"/><FilterOption id="767" count="17" label="Colon tumor"/><FilterOption id="88" count="17" label="Cystic fibrosis"/><FilterOption id="153" count="17" label="Hepatitis C virus infection"/><FilterOption id="1767" count="17" label="Hepatocellular carcinoma"/><FilterOption id="1766" count="17" label="Renal cell carcinoma"/><FilterOption id="3257" count="17" label="Stage IV melanoma"/><FilterOption id="1226" count="16" label="Age related macular degeneration"/><FilterOption id="616" count="16" label="Graft versus host disease"/><FilterOption id="199" count="16" label="Leukemia"/><FilterOption id="233" count="16" label="Neurodegenerative disease"/><FilterOption id="239" count="16" label="Ocular disease"/><FilterOption id="161" count="15" label="Hodgkins disease"/><FilterOption id="318" count="15" label="Systemic lupus erythematosus"/><FilterOption id="347" count="15" label="Wound healing"/><FilterOption id="55" count="14" label="Cardiac failure"/><FilterOption id="1011" count="14" label="Esophagus tumor"/><FilterOption id="185" count="14" label="Immune disorder"/><FilterOption id="836" count="14" label="Insulin dependent diabetes"/><FilterOption id="4250" count="14" label="Metastatic renal cell carcinoma"/><FilterOption id="210" count="14" label="Migraine"/><FilterOption id="224" count="14" label="Myocardial infarction"/><FilterOption id="760" count="13" label="Brain tumor"/><FilterOption id="1069" count="13" label="Metastasis"/><FilterOption id="286" count="13" label="Renal disease"/><FilterOption id="2454" count="12" label="Glioblastoma"/><FilterOption id="191" count="12" label="Influenza virus infection"/><FilterOption id="3665" count="12" label="Metastatic non small cell lung cancer"/><FilterOption id="245" count="12" label="Osteoarthritis"/><FilterOption id="427" count="12" label="Uterine cervix tumor"/><FilterOption id="33" count="11" label="Atherosclerosis"/><FilterOption id="95" count="11" label="Dermatological disease"/><FilterOption id="1749" count="11" label="Diffuse large B-cell lymphoma"/><FilterOption id="1127" count="11" label="Fibrosis"/><FilterOption id="134" count="11" label="Glaucoma"/><FilterOption id="178" count="11" label="Hypertension"/><FilterOption id="584" count="11" label="Lipid metabolism disorder"/><FilterOption id="203" count="11" label="Lymphoma"/><FilterOption id="1240" count="11" label="Mesothelioma"/><FilterOption id="1867" count="11" label="Pulmonary hypertension"/><FilterOption id="34" count="10" label="Attention deficit hyperactivity disorder"/><FilterOption id="653" count="10" label="Bipolar disorder"/><FilterOption id="54" count="10" label="Carcinoma"/><FilterOption id="353" count="10" label="Cognitive disorder"/><FilterOption id="1559" count="10" label="Congestive heart failure"/><FilterOption id="152" count="10" label="Hepatitis B virus infection"/><FilterOption id="3666" count="10" label="Metastatic stomach cancer"/><FilterOption id="1128" count="10" label="Neuroendocrine tumor"/><FilterOption id="2637" count="10" label="Non-alcoholic steatohepatitis"/><FilterOption id="711" count="10" label="Respiratory disease"/></Filter><Filter label="Regulatory Designations" name="drugRegulatoryDesignations" total="19"><FilterOption id="1" count="1190" label="Orphan Drug"/><FilterOption id="2" count="499" label="Fast Track"/><FilterOption id="3" count="155" label="Breakthrough Therapy"/><FilterOption id="11" count="139" label="Priority Review"/><FilterOption id="9" count="131" label="Paediatric Investigation Plan"/><FilterOption id="5" count="84" label="Accelerated Approval"/><FilterOption id="13" count="70" label="Rare Pediatric Disease"/><FilterOption id="12" count="51" label="Qualified Infectious Disease Product"/><FilterOption id="10" count="31" label="PRIME"/><FilterOption id="17" count="23" label="Regenerative Medicine Advanced Therapy"/><FilterOption id="16" count="22" label="Promising Innovative Medicine"/><FilterOption id="14" count="14" label="Sakigake"/><FilterOption id="4" count="12" label="Advanced Therapy Medicinal Product"/><FilterOption id="6" count="8" label="Animal Rule"/><FilterOption id="7" count="7" label="Emergency Use Authorization"/><FilterOption id="19" count="6" label="Special Review Project"/><FilterOption id="18" count="5" label="National Science and Technology Major Project"/><FilterOption id="8" count="3" label="New Active Substance"/><FilterOption id="15" count="1" label="Tropical Disease Priority Review"/></Filter><Filter label="Primary Actions" name="actionsPrimary" total="100"><FilterOption id="5023" count="84" label="CD3 modulator"/><FilterOption id="67136" count="69" label="Programmed cell death protein 1 inhibitor"/><FilterOption id="3756" count="68" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="740" count="61" label="Epidermal growth factor receptor antagonist"/><FilterOption id="14007" count="61" label="Programmed cell death ligand 1 inhibitor"/><FilterOption id="5080" count="59" label="B-lymphocyte antigen CD19 modulator"/><FilterOption id="3755" count="52" label="Erbb2 tyrosine kinase receptor modulator"/><FilterOption id="381" count="49" label="TNF alpha ligand inhibitor"/><FilterOption id="293" count="47" label="Opioid receptor mu agonist"/><FilterOption id="1722" count="46" label="VEGF receptor antagonist"/><FilterOption id="287" count="44" label="Opioid receptor agonist"/><FilterOption id="795" count="43" label="Cannabinoid receptor agonist"/><FilterOption id="721" count="43" label="TNF binding agent"/><FilterOption id="498" count="42" label="Sodium channel inhibitor"/><FilterOption id="132" count="39" label="Cyclooxygenase inhibitor"/><FilterOption id="2585" count="38" label="Glucagon-like peptide 1 receptor agonist"/><FilterOption id="5482" count="36" label="Cytotoxic T-lymphocyte protein-4 inhibitor"/><FilterOption id="3848" count="36" label="VEGF-2 receptor antagonist"/><FilterOption id="3191" count="35" label="Glucocorticoid receptor agonist"/><FilterOption id="624" count="35" label="Progesterone receptor agonist"/><FilterOption id="12521" count="35" label="VEGF ligand inhibitor"/><FilterOption id="7343" count="33" label="Beta amyloid antagonist"/><FilterOption id="1001" count="33" label="Cyclooxygenase 2 inhibitor"/><FilterOption id="138" count="33" label="DNA polymerase inhibitor"/><FilterOption id="3085" count="30" label="IL-15 receptor agonist"/><FilterOption id="621" count="29" label="Amyloid protein deposition inhibitor"/><FilterOption id="3592" count="29" label="Btk tyrosine kinase inhibitor"/><FilterOption id="199" count="29" label="Histamine H1 receptor antagonist"/><FilterOption id="281" count="29" label="NMDA receptor antagonist"/><FilterOption id="3846" count="28" label="VEGF-1 receptor antagonist"/><FilterOption id="8255" count="27" label="APRIL receptor modulator"/><FilterOption id="5085" count="27" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="2574" count="27" label="Histone deacetylase inhibitor"/><FilterOption id="142" count="27" label="Topoisomerase II inhibitor"/><FilterOption id="150" count="26" label="Dopamine D2 receptor antagonist"/><FilterOption id="675" count="26" label="Hepatocyte growth factor receptor antagonist"/><FilterOption id="141" count="26" label="Topoisomerase I inhibitor"/><FilterOption id="86" count="25" label="Beta lactamase inhibitor"/><FilterOption id="1919" count="25" label="Insulin sensitizer"/><FilterOption id="1575" count="25" label="Phosphoinositide 3-kinase inhibitor"/><FilterOption id="2653" count="24" label="Nuclear factor kappa B inhibitor"/><FilterOption id="10232" count="23" label="CFTR modulator"/><FilterOption id="20949" count="23" label="DMD gene modulator"/><FilterOption id="431" count="23" label="DNA gyrase inhibitor"/><FilterOption id="3151" count="23" label="GCSF receptor agonist"/><FilterOption id="259" count="23" label="Muscarinic receptor antagonist"/><FilterOption id="60" count="22" label="Androgen receptor antagonist"/><FilterOption id="3808" count="22" label="Kit tyrosine kinase inhibitor"/><FilterOption id="10240" count="22" label="mTOR inhibitor"/><FilterOption id="24308" count="22" label="SCN9A sodium channel subunit inhibitor"/><FilterOption id="33" count="21" label="Alpha 2 adrenoceptor agonist"/><FilterOption id="8805" count="21" label="AMP activated protein kinase stimulator"/><FilterOption id="5083" count="21" label="B-lymphocyte antigen CD20 modulator"/><FilterOption id="40" count="21" label="Beta 2 adrenoceptor agonist"/><FilterOption id="93" count="21" label="Calcium channel inhibitor"/><FilterOption id="5450" count="21" label="CDw137 agonist"/><FilterOption id="3605" count="21" label="Epidermal growth factor receptor modulator"/><FilterOption id="32076" count="21" label="Mucin 1 modulator"/><FilterOption id="81" count="20" label="Benzodiazepine receptor agonist"/><FilterOption id="34570" count="20" label="Bromodomain containing protein 4 inhibitor"/><FilterOption id="2581" count="20" label="Cannabinoid CB2 receptor agonist"/><FilterOption id="286" count="20" label="Estrogen receptor antagonist"/><FilterOption id="9267" count="20" label="Glutamate carboxypeptidase II modulator"/><FilterOption id="3562" count="20" label="Jak1 tyrosine kinase inhibitor"/><FilterOption id="1832" count="20" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="541" count="20" label="Tubulin receptor antagonist"/><FilterOption id="59" count="19" label="Androgen receptor agonist"/><FilterOption id="144" count="19" label="Dopamine receptor agonist"/><FilterOption id="401" count="19" label="Estrogen receptor agonist"/><FilterOption id="52970" count="19" label="GCSF ligand"/><FilterOption id="1833" count="19" label="Non-nucleoside reverse transcriptase inhibitor"/><FilterOption id="288" count="19" label="Opioid receptor antagonist"/><FilterOption id="372" count="19" label="Thymidylate synthase inhibitor"/><FilterOption id="585" count="18" label="5-HT 2a receptor antagonist"/><FilterOption id="151630" count="18" label="CRISPR associated endonuclease Cas9 modulator"/><FilterOption id="3754" count="18" label="EGFR family tyrosine kinase receptor inhibitor"/><FilterOption id="536" count="18" label="Estradiol agonist"/><FilterOption id="778" count="18" label="PDE 5 inhibitor"/><FilterOption id="3806" count="17" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="3560" count="17" label="JAK tyrosine kinase inhibitor"/><FilterOption id="74517" count="17" label="Tau protein inhibitor"/><FilterOption id="28" count="16" label="Adrenergic receptor agonist"/><FilterOption id="38" count="16" label="Beta adrenoceptor antagonist"/><FilterOption id="4010" count="16" label="Calcineurin inhibitor"/><FilterOption id="2579" count="16" label="Cannabinoid CB1 receptor agonist"/><FilterOption id="5537" count="16" label="Dipeptidyl peptidase IV inhibitor"/><FilterOption id="19115" count="16" label="HLA class I antigen A-2 alpha modulator"/><FilterOption id="15" count="15" label="5-HT 3 receptor antagonist"/><FilterOption id="2421" count="15" label="Beta amyloid synthesis inhibitor"/><FilterOption id="115" count="15" label="Factor VIII agonist"/><FilterOption id="12358" count="15" label="Hepatitis C virus NS5B polymerase inhibitor"/><FilterOption id="1016" count="15" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="434" count="15" label="PGF2 alpha agonist"/><FilterOption id="30009" count="15" label="Wilms tumor protein modulator"/><FilterOption id="149" count="14" label="Dopamine D2 receptor agonist"/><FilterOption id="12162" count="14" label="Erythropoietin ligand"/><FilterOption id="205" count="14" label="HMG CoA reductase inhibitor"/><FilterOption id="471" count="14" label="IL-6 receptor antagonist"/><FilterOption id="23014" count="14" label="Insulin ligand"/><FilterOption id="400" count="14" label="Insulin receptor agonist"/></Filter><Filter label="Primary Companies" name="companiesPrimary" total="100"><FilterOption id="18767" count="297" label="Pfizer Inc"/><FilterOption id="18077" count="223" label="Merck &amp; Co Inc"/><FilterOption id="1072507" count="139" label="AbbVie Inc"/><FilterOption id="19453" count="97" label="Genentech Inc"/><FilterOption id="1013295" count="95" label="Astellas Pharma Inc"/><FilterOption id="14109" count="84" label="Amgen Inc"/><FilterOption id="16450" count="78" label="Gilead Sciences Inc"/><FilterOption id="17269" count="67" label="Ionis Pharmaceuticals Inc"/><FilterOption id="1005244" count="59" label="Biogen Inc"/><FilterOption id="17058" count="56" label="Bausch Health Companies Inc"/><FilterOption id="1009547" count="54" label="Sanofi SA"/><FilterOption id="25863" count="53" label="Janssen Pharmaceuticals Inc"/><FilterOption id="19214" count="53" label="Regeneron Pharmaceuticals Inc"/><FilterOption id="1014227" count="51" label="WuXi PharmaTech (Cayman) Inc"/><FilterOption id="26997" count="48" label="Janssen Biotech Inc"/><FilterOption id="28355" count="45" label="GlaxoSmithKline plc"/><FilterOption id="22403" count="45" label="Inovio Pharmaceuticals Inc"/><FilterOption id="20300" count="41" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="14190" count="40" label="AstraZeneca plc"/><FilterOption id="1061563" count="40" label="PanGen Biotech Inc"/><FilterOption id="23137" count="39" label="Novartis AG"/><FilterOption id="15872" count="34" label="Eisai Co Ltd"/><FilterOption id="1048574" count="34" label="Sorrento Therapeutics Inc"/><FilterOption id="1016672" count="32" label="3SBio Inc"/><FilterOption id="26879" count="31" label="Novartis Institutes for BioMedical Research Inc"/><FilterOption id="14240" count="31" label="Sarepta Therapeutics Inc"/><FilterOption id="29927" count="30" label="Alnylam Pharmaceuticals Inc"/><FilterOption id="15615" count="28" label="Dana-Farber Cancer Institute Inc"/><FilterOption id="20739" count="28" label="Vertex Pharmaceuticals Inc"/><FilterOption id="1088700" count="27" label="Allergan plc"/><FilterOption id="29060" count="27" label="MacroGenics Inc"/><FilterOption id="1015036" count="27" label="NantKwest Inc"/><FilterOption id="27477" count="27" label="Paladin Labs Inc"/><FilterOption id="20658" count="27" label="University of Pennsylvania"/><FilterOption id="19986" count="26" label="Handok Inc"/><FilterOption id="19446" count="26" label="Roche Holding AG"/><FilterOption id="1113858" count="26" label="Seqirus"/><FilterOption id="15414" count="25" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="17332" count="25" label="Johnson &amp; Johnson"/><FilterOption id="14881" count="24" label="Boehringer Ingelheim International GmbH"/><FilterOption id="1070750" count="24" label="Innovent Biologics Inc"/><FilterOption id="25554" count="24" label="Seattle Genetics Inc"/><FilterOption id="14455" count="23" label="Bayer AG"/><FilterOption id="1042596" count="23" label="Kyowa Hakko Kirin Co Ltd"/><FilterOption id="13601" count="22" label="Abbott Laboratories"/><FilterOption id="14061" count="22" label="Almirall Prodesfarma SA"/><FilterOption id="1003633" count="22" label="Amicus Therapeutics Inc"/><FilterOption id="15065" count="22" label="Bristol-Myers Squibb Co"/><FilterOption id="1017506" count="22" label="Daiichi Sankyo Co Ltd"/><FilterOption id="1049660" count="22" label="Hualan Biological Engineering Inc"/><FilterOption id="1035060" count="22" label="Mitsubishi Tanabe Pharma Corp"/><FilterOption id="18439" count="22" label="Mylan NV"/><FilterOption id="25162" count="22" label="Sangamo Therapeutics Inc"/><FilterOption id="15331" count="21" label="Celgene Corp"/><FilterOption id="1038723" count="21" label="Integrated BioTherapeutics Inc"/><FilterOption id="22122" count="21" label="Memorial Sloan-Kettering Cancer Center"/><FilterOption id="18090" count="21" label="Merck Sharp &amp; Dohme Ltd"/><FilterOption id="18681" count="21" label="Ono Pharmaceutical Co Ltd"/><FilterOption id="1135041" count="20" label="ABL Bio Inc"/><FilterOption id="1161108" count="20" label="Biosion Inc"/><FilterOption id="1056870" count="20" label="Kite Pharma Inc"/><FilterOption id="1104834" count="20" label="NantCell Inc"/><FilterOption id="19858" count="20" label="Sunovion Pharmaceuticals Inc"/><FilterOption id="1011990" count="19" label="Emergent BioSolutions Inc"/><FilterOption id="17202" count="19" label="ImmunoGen Inc"/><FilterOption id="1039453" count="19" label="Innovation Pharmaceuticals Inc"/><FilterOption id="23221" count="18" label="Agenus Inc"/><FilterOption id="16284" count="18" label="bluebird bio Inc"/><FilterOption id="1070979" count="18" label="GigaGen Inc"/><FilterOption id="17204" count="18" label="Immunomedics Inc"/><FilterOption id="1007316" count="18" label="Perseus Proteomics Inc"/><FilterOption id="1021184" count="18" label="Profectus BioSciences Inc"/><FilterOption id="20348" count="18" label="Teva Pharmaceutical Industries Ltd"/><FilterOption id="1046898" count="17" label="Cannabis Science Inc"/><FilterOption id="27692" count="17" label="Cellectar Biosciences Inc"/><FilterOption id="1080369" count="17" label="Cellular Biomedicine Group Inc"/><FilterOption id="1093663" count="17" label="Knight Therapeutics Inc"/><FilterOption id="20519" count="17" label="National Cancer Institute"/><FilterOption id="1009170" count="16" label="Cipher Pharmaceuticals Inc"/><FilterOption id="1028220" count="16" label="Intas Pharmaceuticals Ltd"/><FilterOption id="17327" count="16" label="Japan Tobacco Inc"/><FilterOption id="1043354" count="16" label="Mapp Biopharmaceutical Inc"/><FilterOption id="19863" count="16" label="Servier"/><FilterOption id="19898" count="16" label="Shionogi &amp; Co Ltd"/><FilterOption id="1034793" count="16" label="Tris Pharma Inc"/><FilterOption id="1022888" count="16" label="Vaxart Inc"/><FilterOption id="22881" count="15" label="Abeona Therapeutics Inc"/><FilterOption id="15587" count="15" label="Daewoong Pharmaceutical Co Ltd"/><FilterOption id="1036293" count="15" label="Fate Therapeutics Inc"/><FilterOption id="1063219" count="15" label="Guangdong Zhongsheng Pharmaceutical Co Ltd"/><FilterOption id="1022379" count="15" label="Hikma Pharmaceuticals plc"/><FilterOption id="1033982" count="15" label="Insys Therapeutics Inc"/><FilterOption id="29796" count="15" label="Momenta Pharmaceuticals Inc"/><FilterOption id="15358" count="14" label="Cephalon Inc"/><FilterOption id="1040605" count="14" label="Dicerna Pharmaceuticals Inc"/><FilterOption id="1053219" count="14" label="Eureka Therapeutics Inc"/><FilterOption id="30564" count="14" label="GeoVax Labs Inc"/><FilterOption id="16587" count="14" label="Grunenthal GmbH"/><FilterOption id="24019" count="14" label="MSD Japan"/><FilterOption id="30752" count="14" label="Onconova Therapeutics Inc"/></Filter><Filter label="Highest Phase" name="phaseHighest" total="9"><FilterOption id="DR" count="5887" label="Discovery"/><FilterOption id="L" count="1306" label="Launched"/><FilterOption id="C2" count="1221" label="Phase 2 Clinical"/><FilterOption id="C1" count="997" label="Phase 1 Clinical"/><FilterOption id="C3" count="398" label="Phase 3 Clinical"/><FilterOption id="CU" count="112" label="Clinical"/><FilterOption id="PR" count="90" label="Pre-registration"/><FilterOption id="R" count="46" label="Registered"/><FilterOption id="S" count="43" label="Suspended"/></Filter></Filters></drugResultsOutput>